PMID- 11824241 OWN - NLM STAT- MEDLINE DCOM- 20020320 LR - 20161021 IS - 1868-1050 (Print) IS - 1868-1050 (Linking) VI - 118 DP - 2001 TI - [Long-term drug therapy versus antireflux surgery in chronic reflux]. PG - 177-80 AB - In endoscopy-negative reflux disease just 25% remain in remission after drug therapy, in reflux oesophagitis only 10%. Long-term management is therefore mandatory in this quality of life-impairing chronic disorder. Following the GENVAL consensus conference proton pump inhibitors (PPI) should be used primarily in a step-down regimen; isomeric PPIs reduce duration of acute therapy by 50%. According to Klinkenberg-Knol et al. 100% of all patients with H2-resistant reflux oesophagitis are asymptomatic and free of recurrency when dosage of PPI is adapted to a higher level. The same result was obtained in the prospective study by Lundell et al. comparing fundoplication and long-term management with omeprazole for 3 years. FAU - Rosch, W AU - Rosch W AD - Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt/M. LA - ger PT - Comparative Study PT - English Abstract PT - Journal Article TT - Medikamentose Dauertherapie versus Antirefluxchirurgie bei der chronischen Refluxkrankheit. PL - Germany TA - Kongressbd Dtsch Ges Chir Kongr JT - Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress JID - 100959225 RN - 0 (Anti-Ulcer Agents) RN - 0 (Proton Pump Inhibitors) SB - IM MH - Anti-Ulcer Agents/*administration & dosage MH - Clinical Trials as Topic MH - Esophagitis, Peptic/*drug therapy/surgery MH - Fundoplication MH - Gastroesophageal Reflux/*drug therapy/surgery MH - Humans MH - Long-Term Care MH - *Proton Pump Inhibitors MH - Quality of Life MH - Recurrence MH - Treatment Outcome EDAT- 2002/02/05 10:00 MHDA- 2002/03/21 10:01 CRDT- 2002/02/05 10:00 PHST- 2002/02/05 10:00 [pubmed] PHST- 2002/03/21 10:01 [medline] PHST- 2002/02/05 10:00 [entrez] PST - ppublish SO - Kongressbd Dtsch Ges Chir Kongr. 2001;118:177-80.